61st American Society of Hematology (ASH 2019) Annual Meeting & Exposition

Event Date: December 7 - 10, 2019

Event Location: Booth 971, Orange County Convention Center (OCCC), Orlando, FL


Diapharma is will attend and exhibit at the 61st American Society of Hematology (ASH 2019) Annual Meeting & Exposition this year. Please click here to schedule a meeting with us or email us directly.

Diapharma Booth 971

Technoclone Booth 969

ASH 2019

The 61st ASH Annual Meeting and Exposition will be the world’s most comprehensive hematology event of 2019. The meeting will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Network with top minds in the field and a global community of more than 25,000 hematology professionals from every subspecialty.

hematology assay test kit chromogenic ELISAAbout ASH

The American Society of Hematology (ASH) is the world’s largest professional society concerned with understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. ASH is dedicated to helping hematologists conquer blood diseases.

The field of hematology has experienced a recent surge in progress thanks to novel technologies, mechanistic insights, and cutting-edge therapeutic strategies that have driven significant and meaningful advances in the quality of care. These foundational insights are reframing modern research with the continued goal of improving outcomes and discovering cures for the most challenging hematologic diseases.

Whereas certain blood disorders have benefited from the tremendous progress in clinical research and development of new therapies, other areas have continuing challenges such as disease heterogeneity and the complex combinations of genetic drivers that have evaded effective treatment to date. A wide variety of blood-related diseases – from malignancies such as lymphoma and leukemia, to non-malignant diseases including hemoglobinopathies, blood platelet, and coagulation disorders, including orphan diseases of the hematopoietic system – continue to be associated hematology assay test kitwith significant morbidity and mortality and demand attention to reduce their burden and improve the quality of care worldwide.

Today, the research community looks to emerging technologies and tools in the areas of genetics and epigenetics, gene therapies, and regenerative medicine to identify areas that have strong potential to make a dramatic impact on patient care across a range of diseases.

The ASH agenda serves as a roadmap for the prioritization of research support across the hematology community, including recommendations for dedicated resources from funding agencies and foundations that will equip researchers today and in the future to make truly practice-changing discoveries. These specific and critically important research questions must be answered to gain the insights that will launch the field into the next generation of care for hematologic conditions.

ASH publishes BloodThe HematologistASH Clinical NewsASH Self-Assessment Program, and the Hematology ASH Education Program.

ASH | ASH 2019 | Facebook | Twitter | LinkedInYouTube | OCCC